No 10Y consistency score for revenue — its stored periods are half-year spaced, so quarter-over-same-quarter consistency is not computed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 25
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Eloxx Pharmaceuticals, Inc. (ELOX) stock was $14.57 as of Oct 6, 2026, 12:25 PM EDT, down 5.45% from the previous close.
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons.
Biotechnology · Watertown, MA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.61
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.66
vs Estimate
$-70.40
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ELOX | $50.07M | $14.57 | -5.45% | N/A | N/A | N/A | N/A |
| 2MBOT | $49.90M | $1.09 | +2.34% | -64.98% | -31.63% | -39.57% | vs ELOX |
| 3APLM | $49.89M | $22.72 | -2.35% | +26.12% | N/A | N/A | vs ELOX |
| 4INMB | $50.51M | $1.90 | -2.06% | -6.70% | -36.88% | N/A | vs ELOX |
| 5CELU | $50.80M | $1.75 | +2.63% | -19.63% | -52.57% | N/A | vs ELOX |
| 6COCH | $50.96M | $0.66 | +1.40% | -19.94% | -41.73% | N/A | vs ELOX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 4 analysts
Average Price Target
$38.25
+162.5% upside
Low
$32.00
Current
$14.57
High
$43.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.65 | $-0.61 | $-0.57 | 2 |
| Quarter ending Dec 2026 | $-0.72 | $-0.69 | $-0.67 | 2 |
| Quarter ending Mar 2027 | $-0.74 | $-0.74 | $-0.74 | 1 |
| Quarter ending Jun 2027 | $-0.78 | $-0.78 | $-0.78 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.85 | $-2.10 | $-0.99 | 2 |
| FY 2027 | $-3.58 | $-2.70 | $-1.82 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $1.75M | $1.75M | $1.75M | 1 |
| Quarter ending Mar 2027 | $1.75M | $1.75M | $1.75M | 1 |
| Quarter ending Jun 2027 | $1.75M | $1.75M | $1.75M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $173.81M | $173.81M | $173.81M | 1 |
